肾康栓对于慢性肾脏病的治疗效果及临床应用  

To Investigate the Therapeutic Effect and Clinical Application of Shenkang Suppository on Chronic Renal Disease

作　　者：黄馨[1] 白瑜[1] 于李汀[1] 曹烁[1] 郑黎强[2] 黄东辉[2] 李德天[1] HUANG Xin BAI Yu YU Li-ding et al(Department of Nephrology , the Affiliated Shengjing Hospital of China Medical University, Shenyang 110004, China)

机构地区：[1]中国医科大学附属盛京医院肾内科,辽宁沈阳110004 [2]中国医科大学附属盛京医院临床流行病学研究室,辽宁沈阳110004

出　　处：《医学与哲学（B）》2017年第8期35-37,49,共4页Medicine & Philosophy(B)

摘　　要：将盛京医院肾内科2016年1月至2016年12月收治的90名慢性肾脏病2期、3期和4期患者随机分为对照组和肾康栓组,相同基础治疗,肾康栓组加用肾康栓肛入,比较两组疗效差异。结果显示肾康栓组治疗后血肌酐、血清胱抑素C明显下降(P<0.01),血尿素氮、血清尿酸下降(P<0.05),血红蛋白显著升高(P<0.01);而对照组治疗前后仅血红蛋白上升具有差异性(P<0.05)。两组患者按照早期及中晚期肾功能不全进行分层分析后结果显示肾康栓能够明显改善慢性肾脏病患者的相关指标,对于指标异常程度较小的早期患者疗效更加显著,具有明显延缓其疾病进展作用。The patients were randomly divided into control group and Shenkang suppository group （n=45） in patients with chronic kidney disease from January 2016 to December 2016 in Shengjing Hospital.Two groups of patients with the same basic treatment, Shenkang group plus Shenkang bolt anal into, compared the difference between the two groups.The serum creatinine and serum cystatin C were significantly decreased after treatment with Shenkang group （P〈0.01）, blood urea nitrogen, serum uric acid decreased （P〈0.05）, at the same time, the hemoglobin of the patients was significantly increased （P〈0.01）, while there was no difference in the control group before and after treatment except that the difference of hemoglobin was significant （P〈0.05）.Two groups of patients in early and mid renal insufficiency after stratification analysis results show that the Shenkang Suppository group can obviously improve the relevant indexes of patients with chronic kidney disease , for small degree of abnormal in patients with early, more significant, has significantly slow the disease progression.

关 键 词：慢性肾脏病 肾康栓 血肌酐 胱抑素C 尿酸 

分 类 号：R692[医药卫生—泌尿科学]